Cancer Therapy

You have full text access to this OnlineOpen article

Vascular targeting by EndoTAG™-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer

  1. Martin E. Eichhorn1,2,†,*,
  2. Ivan Ischenko1,
  3. Siiri Luedemann2,
  4. Sebastian Strieth2,3,
  5. Armine Papyan1,
  6. Alexander Werner4,
  7. Hermann Bohnenkamp5,
  8. Eric Guenzi5,
  9. Gerhard Preissler1,
  10. Uwe Michaelis5,
  11. Karl-Walter Jauch1,
  12. Christiane J. Bruns1,
  13. Marc Dellian3

Article first published online: 20 AUG 2009

DOI: 10.1002/ijc.24846

Issue

International Journal of Cancer

International Journal of Cancer

Volume 126, Issue 5, pages 1235–1245, 1 March 2010

Additional Information

How to Cite

Eichhorn, M. E., Ischenko, I., Luedemann, S., Strieth, S., Papyan, A., Werner, A., Bohnenkamp, H., Guenzi, E., Preissler, G., Michaelis, U., Jauch, K.-W., Bruns, C. J. and Dellian, M. (2010), Vascular targeting by EndoTAG™-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int. J. Cancer, 126: 1235–1245. doi: 10.1002/ijc.24846

Author Information

  1. 1

    Department of Surgery, Klinikum Grosshadern, University of Munich, Munich, Germany

  2. 2

    Walter Brendel Center for Experimental Medicine, University of Munich, Munich, Germany

  3. 3

    Department of Otorhinolaryngology, Klinikum Grosshadern, University of Munich, Munich, Germany

  4. 4

    Bioservice Scientific Laboratories GmbH, Planegg, Germany

  5. 5

    Medigene AG, Planegg, Germany

  1. †

    Fax: +4989-2443-40591

*Department of Surgery, Klinikum Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany

Publication History

  1. Issue published online: 27 DEC 2009
  2. Article first published online: 20 AUG 2009
  3. Accepted manuscript online: 20 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 3 AUG 2009
  5. Manuscript Received: 21 FEB 2009

Funded by

  • The FöFoLe Research Program, University of Munich. Grant Number: Nr. 379
  • The Bavarian Research Foundation. Grant Number: Nr. AZ-652-05

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1001K)

References

  • 1
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.
  • 2
    Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 1984; 23: 217–25.
  • 3
    Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 1999; 29: 733–6.
  • 4
    Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5: 436–46.
  • 5
    Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101: 1401–13.
  • 6
    Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003; 105: 561–7.
  • 7
    Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009; 98: 411–29.
  • 8
    Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003; 9: 2335–41.
  • 9
    Eichhorn ME, Luedemann S, Strieth S, Papyan A, Ruhstorfer H, Haas H, Michaelis U, Sauer B, Teifel M, Enders G, Brix G, Jauch KW, Bruns CJ, Dellian M. Cationic lipid complexed camptothecin (EndoTAG((R))-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther 2007; 6: 920–9.
  • 10
    Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110: 117–24.
  • 11
    Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Teifel M, Ruhstorfer H, Michaelis U, Griebel J, Brix G, Jauch KW, Dellian M. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther 2006; 5: 89–96.
  • 12
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
  • 13
    United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia, 2nd edn. Br J Cancer 1998; 77: 1–10.
  • 14
    Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999; 1: 50–62.
  • 15
    Michaelis U, Teifel M. Cationic lipid complexes to target tumor endothelium. In: SiemannDW, ed. Vascular-targeted therapies in oncology. Gainesville: John Wiley & Sons Ltd, Chapter 13, 2006, 221–40.
  • 16
    Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009; 98: 411–29.
  • 17
    Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized”. SCID mouse model. J Invest Dermatol 2003; 120: 476–82.
  • 18
    Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 2008; 122: 452–60.
  • 19
    Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 2007; 337: 329–35.
  • 20
    Kalra AV, Campbell RB. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting. Pharm Res 2006; 23: 2809–17.
  • 21
    Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP, Munn LL. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002; 62: 6831–6.
  • 22
    Wirrwar A, Buchholz D, Gottschalk O, Viehover S, Schramm NU, Muller HW. Dynamic observation of the three-dimensional distribution of labeled liposomes using the novel high-resolution single-photon emission computed tomography. Mol Imaging 2008; 7: 234–8.
  • 23
    Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, Ryan AJ, Giavazzi R. Potential antagonism of tubulin-binding anticancer agents in combination therapies. Clin Cancer Res 2005; 11: 2720–6.
  • 24
    Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer. 2007; 97: 888–94.
  • 25
    Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 1984; 49: 405–13.
  • 26
    Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65: 2433–40.
  • 27
    Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, Braguer D. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004; 3: 1301–10.
  • 28
    Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U, Berghaus A, Dellian M. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res 2008; 14: 4603–11.
  • 29
    Löhr M, Haas S, Bechstein W, Karrasch M, Mescheder A, Meyer I, Bodoky G, Pap A, Jäger D, Fölsch UR. First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT - phase II study. J Clin Oncol 2008; 26: 4618.
  • 30
    Loehr M, Bodoky G, Fölsch U, Märten A, Karrasch M, Lilla C, Meyer I, Osinsky D, Szanto J, Lutz M. Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial. J Clin Oncol 2009; 27: 4526.
View Full Article (HTML) Get PDF (1001K)